Cancer

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…

6 months ago

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…

6 months ago

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare…

6 months ago

Koning Health Brings Advanced Breast Imaging Technology to Bedford Breast Center in Beverly Hills

BEVERLY HILLS, Calif., July 11, 2024 /PRNewswire/ -- Koning Health is excited to announce the upcoming installation of its innovative Koning…

6 months ago

Induced Pluripotent Stem Cells Market Size is Expected to Grow at a CAGR of 9.4% and Reach USD 4.6 billion by 2034: Transparency Market Research Inc.

Induced pluripotent stem cells are experiencing strong growth due to rising research into disease models and drug discovery.  WILMINGTON, Del. ,…

6 months ago

Lucid Diagnostics Launches New Corporate Website

NEW YORK, July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics…

6 months ago

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and…

6 months ago

Element Biosciences Raises Over $277 Million to Develop and Commercialize Differentiated Products and Continue Rapid Growth

SAN DIEGO, July 11, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced over $277…

6 months ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract – Now 12-Month Data

CARDIFF, UK / ACCESSWIRE / July 11, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company developing a…

6 months ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas TherapeuticsFirst instance decision on…

6 months ago